The results from the trial showed an objective response rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
The involved around 58 patients with advanced RAI refractory DTC whose disease had progressed during the prior 12 months.
Currently, Eisai is engaged in advancing its products like Halaven, lenvatinib and farletuzumab (MORAb-003), for the treatment of breast, ovarian, thyroid, endometrial and other types of cancer in the women’s oncology arena.